Core Viewpoint - The company NuoVasive (688105.SH) has recently obtained CE IVDR certification for its six respiratory pathogen nucleic acid testing kits, allowing sales in EU countries and those recognizing EU CE certification [1] Group 1: Product Details - The product is named Logilet Respiratory Pathogen Panel, designed for auxiliary diagnosis of respiratory syncytial virus, influenza A virus, influenza B virus, severe acute respiratory syndrome coronavirus 2, adenovirus, and Mycoplasma pneumoniae infections [1] - The testing kits are integrated with the company's digital microfluidic Logilet Logicore detection system, which utilizes microfluidic chips for the entire process of nucleic acid extraction, amplification, and detection [1] Group 2: Operational Efficiency - The system aims to provide a fully automated gene testing solution that allows for "sample in, result out," enhancing safety, efficiency, portability, and speed in clinical testing, disease control and prevention, and scientific research applications [1]

Core Viewpoint - The company NuoVance (688105.SH) has recently obtained CE IVDR certification for six nucleic acid testing kits for respiratory pathogens, allowing sales in EU countries and countries recognizing EU CE certification [1] Group 1 - The six nucleic acid testing kits are specifically designed for respiratory pathogens [1] - The CE IVDR certification is a significant regulatory milestone that enables the company to expand its market reach [1] - The certification allows the company to sell its products in the European Union and other countries that accept EU CE certification [1]

Core Viewpoint - The company Novogene (688105.SH) has recently obtained CE IVDR certification for six respiratory pathogen nucleic acid testing kits, allowing sales in EU countries and countries that recognize EU CE certification [1] Group 1 - The six respiratory pathogen nucleic acid testing kits have received CE IVDR certification [1] - The certification enables the company to market its products in EU member states and other countries that accept EU CE certification [1]

Core Viewpoint - The company has announced that its six respiratory pathogen nucleic acid testing kits have recently obtained EU CE IVDR certification, allowing for sales in EU countries and countries that recognize EU CE certification [1] Group 1 - The product is designed to work with the company's digital microfluidic Logilet Logicore detection system [1] - The testing process utilizes microfluidic chips to complete the entire workflow of nucleic acid extraction, amplification, and detection [1] - The kits enable precise detection of six respiratory pathogens, facilitating fully automated genetic testing [1]

中国经济网北京12月9日讯 中证指数有限公司2025年11月28日发布关于沪深300、中证500、中证1000、中证A500 等指数定期调整结果的公告。根据指数规则，经指数专家委员会审议，中证指数有限公司决定调整沪深300、中证 500、中证1000、中证A50、中证A100、中证A500等指数样本，于2025年12月12日收市后生效。其中沪深300指数更换 11只样本，中证500指数更换50只样本，中证1000指数更换100只样本，中证A50指数更换4只样本，中证A100指数更换 6只样本，中证A500指数更换20只样本。 诺唯赞于2021年11月15日在上交所科创板上市，发行数量为4001.00万股，发行价格为55.00元/股，保荐机构（主 承销商）为华泰联合证券有限责任公司，保荐代表人为王正睿、李皓。目前该股处于破发状态。 诺唯赞首次公开发行股票募集资金总额为22.01亿元，扣除发行费用后，募集资金净额为21.09亿元。诺唯赞最终募 集资金净额比原计划多9.07亿元。诺唯赞于2021年11月9日披露的招股书显示，该公司拟募集资金12.02亿元，分别用于 公司总部及研发新基地项目、营销网络扩建项目、补充流 ...

中国经济网北京12月9日讯中证指数有限公司2025年11月28日发布关于沪深300、中证500、中证1000、中证A500等指数 定期调整结果的公告。根据指数规则，经指数专家委员会审议，中证指数有限公司决定调整沪深300、中证500、中证 1000、中证A50、中证A100、中证A500等指数样本，于2025年12月12日收市后生效。其中沪深300指数更换11只样本， 中证500指数更换50只样本，中证1000指数更换100只样本，中证A50指数更换4只样本，中证A100指数更换6只样本， 中证A500指数更换20只样本。 调整结果显示，诺唯赞(688105.SH)被调出中证1000指数样本。 | | 调出名单 | | 调入名单 | | --- | --- | --- | --- | | 605222 | 起帆电缆 | 603887 | 城地香江 | | 605368 | 蓝天燃气 | 605099 | 共创草坪 | | 605577 | 龙版传媒 | 602118 | 力鼎光电 | | 688018 | 乐鑫科技 | 602198 | 安德利 | | 688019 | 安集科技 | 688032 | 禾迈股 ...

Industry Overview - Collagen masks are mainstream skincare products focused on anti-aging and repair, utilizing collagen as the core ingredient along with auxiliary components to achieve hydration and skin barrier repair [1][2] - The Chinese mask industry is expected to reach a market size of 72.986 billion yuan in 2024, entering a period of adjustment and transformation, facing growth slowdown and intensified competition [1][6] - The collagen market is experiencing explosive growth, with a compound annual growth rate (CAGR) of 41.9% from 2020 to 2023, and retail scale expected to exceed 269.5 billion yuan by 2030 [1][7] Market Dynamics - The market structure in China shows that sheet masks remain dominant, while cream masks are rapidly growing, focusing on hydration and repair needs [1][7] - The competitive landscape features local leaders dominating, niche players breaking through, and international brands penetrating the market, with a clear price gradient and significant differentiation between high, medium, and low-end markets [1][8] Industry Chain - The upstream of the collagen mask industry primarily uses animal-derived collagen, while recombinant collagen is rapidly developing due to its high purity and compatibility with mask formulations [6][10] - The manufacturing process involves various technologies to convert raw materials into different forms and functions of mask products, with sales channels dominated by online e-commerce and deepening offline professional channels [6][10] Current Development - The Chinese mask industry is transitioning into a phase of deep integration after rapid growth, with three emerging drivers leading market changes: consumption upgrades, male skincare market expansion, and personalized demand fostering innovative scenarios [6][7] - The market size is projected to steadily grow to 76.79 billion yuan by 2025 and potentially exceed 146.42 billion yuan by 2030, indicating robust long-term growth prospects [6][7] Key Players - Major companies in the collagen mask industry include Juzi Biotechnology, Huaxi Biotechnology, and Marubi Biotechnology, leveraging differentiated technologies and channel advantages to lead the market [2][10] - The industry is characterized by a multi-faceted competitive ecosystem, with local leaders, niche players, and international brands all contributing to the market dynamics [10] Future Trends - The industry is expected to advance towards high-end technology, refined products, and standardized ecosystems, with a focus on cross-disciplinary technology integration and precise formulations [10][12] - Regulatory tightening is anticipated to accelerate the elimination of smaller brands, increasing market concentration, while leading companies will strengthen their market positions through R&D innovation and global expansion [10][14]

证券代码：688105 证券简称：诺唯赞 公告编号：2025-055 南京诺唯赞生物科技股份有限公司2025年第二次临时股东会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容的 真实性、准确性和完整性依法承担法律责任。 重要内容提示： ● 本次会议是否有被否决议案：无 一、会议召开和出席情况 （一）股东会召开的时间：2025年12月5日 （二）股东会召开的地点：南京市栖霞区科创路红枫科技园D2栋1楼报告厅 （三）出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及其持有表决权数量的情 况： 表决情况： ■ ■ （四）表决方式是否符合《公司法》及公司章程的规定，股东会主持情况等。 本次股东会由公司董事会召集，董事长曹林先生主持，会议采用现场投票和网络投票相结合的表决方 式。本次股东会的召集和召开程序、出席会议人员资格和召集人资格、会议表决方式和表决结果均符合 《中华人民共和国公司法》及《公司章程》的规定。 （五）公司董事和董事会秘书的列席情况 1、公司在任董事9人，列席8人，独立董事蔡江南先生因公请假，未列席本次会议。 2、董事会秘书黄金先生列席本次会 ...

北京市天元律师事务所 京天股字（2025）第 723 号 致：南京诺唯赞生物科技股份有限公司 南京诺唯赞生物科技股份有限公司（以下简称"公司"）2025 年第二次临时股 东会（以下简称"本次股东会"）采用现场投票与网络投票相结合的方式召开，现场 会议于 2025 年 12 月 5 日下午 15:00 在南京市栖霞区科创路红枫科技园 D2 栋公司 1 楼报告厅召开。北京市天元律师事务所（以下简称"本所"）接受公司聘任，指派 本所律师参加本次股东会现场会议，并根据《中华人民共和国公司法》、《中华人民 共和国证券法》（以下简称"《证券法》"）、《上市公司股东会规则》（以下简称"《股 东会规则》"）以及《南京诺唯赞生物科技股份有限公司章程》（以下简称"《公司 章程》"）等有关规定，就本次股东会的召集、召开程序、出席会议人员的资格、 召集人资格、会议表决程序和表决结果等有关事宜出具本法律意见。 为出具本法律意见，本所律师审查了《南京诺唯赞生物科技股份有限公司第二 届董事会第二十次会议决议公告》、《南京诺唯赞生物科技股份有限公司关于召开 2025 年第二次临时股东会的通知》（以下简称"《召开股东会通知》"）以及本所律 师 ...

证券代码：688105 证券简称：诺唯赞 公告编号：2025-055 南京诺唯赞生物科技股份有限公司 2025年第二次临时股东会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 | 1、出席会议的股东和代理人人数 | 71 | | --- | --- | | 普通股股东人数 | 71 | | 2、出席会议的股东所持有的表决权数量 | 232,121,546 | | 普通股股东所持有表决权数量 | 232,121,546 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的 | 58.3797 | | 比例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 58.3797 | 2、 董事会秘书黄金先生列席本次会议。 （四） 表决方式是否符合《公司法》及公司章程的规定，股东会主持情况等。 本次股东会由公司董事会召集，董事长曹林先生主持，会议采用现场投票和 网络投票相结合的表决方式。本次股东会的召集和召开程序、出席会 ...